California Liver Research Institute | Pasadena, CA

Research site
301 S Fair Avenue Suite 409, Pasadena, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


11 of 38
Status: Active
Trial type: Interventional
Funder type: Industry

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepat...

Cirrhosis, Liver
Drug: Resmetirom
Drug: Placebo

This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohep...

Hypertension, Portal
Liver Cirrhosis
Drug: Placebo
Drug: Avenciguat (BI 685509)

This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this stu...

Active, not recruiting
Hypertension, Portal
Liver Diseases
Drug: Avenciguat (BI 685509)
Drug: Empagliflozin

This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this st...

Active, not recruiting
Hypertension, Portal
Drug: Placebo matching Avenciguat (BI 685509)
Drug: Avenciguat (BI 685509)

The primary objective of this study is to evaluate the effect of setanaxib on alkaline phosphatase (ALP) at Week 24 in participants with PBC and with...

Active, not recruiting
Liver Stiffness
Primary Biliary Cholangitis
Drug: Placebo
Drug: Setanaxib

To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Inco...

Primary Biliary Cholangitis
Drug: Seladelpar 10 mg
Drug: Placebo

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Primary Biliary Cirrhosis
Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected a...

Advanced Neoplasms
Drug: E7386

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)

This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Scler...

Drug: EP547
Drug: Placebo

Trial conditions

Fatty Liver (12 trials)
Non-alcoholic Fatty Live... (12 trials)
Fibrosis (11 trials)
Cholangitis (10 trials)
Liver Cirrhosis (10 trials)
Liver Diseases (9 trials)
Biliary Liver Cirrhosis (7 trials)
Hepatocellular Carcinoma (6 trials)
Carcinoma (5 trials)
Hepatitis B (4 trials)

And 13 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems